Abstract: Disclosed is a vehicle having a breakaway tie rod. The tie rod has a longitudinal axis oriented substantially orthogonal to the longitudinal axis of the vehicle, and includes a rod portion and a receiver portion. The rod portion includes a proximal ball joint disposed at the proximal end and a male coupling section disposed at the distal end. The receiver portion includes a female coupling section disposed at the proximal end, a distal ball joint disposed at the distal end, and a narrowing feature disposed between the proximal end and distal end. The male coupling section of the rod portion is received into the female coupling section of the receiver portion, forming a connection, and the distal end of the rod portion is disposed proximate to the narrowing feature. The narrowing feature is configured to fracture when subjected to a threshold force substantially parallel to the longitudinal axis of the vehicle.

Abstract: Disclosed is a vehicle having a breakaway tie rod. The tie rod has a longitudinal axis oriented substantially orthogonal to the longitudinal axis of the vehicle, and includes a rod portion and a receiver portion. The rod portion includes a proximal ball joint disposed at the proximal end and a male coupling section disposed at the distal end. The receiver portion includes a female coupling section disposed at the proximal end, a distal ball joint disposed at the distal end, and a narrowing feature disposed between the proximal end and distal end. The male coupling section of the rod portion is received into the female coupling section of the receiver portion, forming a connection, and the distal end of the rod portion is disposed proximate to the narrowing feature. The narrowing feature is configured to fracture when subjected to a threshold force substantially parallel to the longitudinal axis of the vehicle.

Abstract: The present invention relates to a composition containing as its main component proanthocyanidin oligomer to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight, which is obtained by heating plant materials containing proanthocyanidin polymer or extract thereof with a substance having a phloroglucinol ring structure or resorcinol ring structure in an acidic aqueous solution, production method thereof, and uses of the composition in health products and pharmaceutical products. According to the invention, proanthocyanidin oligomer having physiological activity, to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight to such a level that the oligomer can be absorbed into living body, which has been conventionally difficult to obtain at high yield from plant raw materials, can be produced efficiently and easily.

Abstract: The present invention relates to a composition containing as its main component proanthocyanidin oligomer to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight, which is obtained by heating plant materials containing proanthocyanidin polymer or extract thereof with a substance having a phloroglucinol ring structure or resorcinol ring structure in an acidic aqueous solution, production method thereof, and uses of the composition in health products and pharmaceutical products. According to the invention, proanthocyanidin oligomer having physiological activity, to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight to such a level that the oligomer can be absorbed into living body, which has been conventionally difficult to obtain at high yield from plant raw materials, can be produced efficiently and easily.

Abstract: Disclosed is a method for producing an antibody directed against a protein, particularly a transmembrane protein, expressed on the surfaces of cells. Specifically disclosed is a means for obtaining a desired antibody by mixing cells capable of expressing an antigen protein on the surfaces thereof (i.e., antigen molecule-expressing cells) with an antibody library composed of antibody-expressing cells, viruses or the like, and subsequently concentrating/isolating only components (e.g., antibody-expressing cells, viruses) capable of binding to the antigen molecule-expressing cells from the components (e.g., antibody-expressing cells, viruses) of the antibody library.

Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.

Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.

Abstract: Disclosed is a method for producing an antibody directed against a protein, particularly a transmembrane protein, expressed on the surfaces of cells. Specifically disclosed is a means for obtaining a desired antibody by mixing cells capable of expressing an antigen protein on the surfaces thereof (i.e., antigen molecule-expressing cells) with an antibody library composed of antibody-expressing cells, viruses or the like, and subsequently concentrating/isolating only components (e.g., antibody-expressing cells, viruses) capable of binding to the antigen molecule-expressing cells from the components (e.g., antibody-expressing cells, viruses) of the antibody library.

Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.

Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.

Abstract: It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen.

Abstract: The present invention provides a novel diagnostic or therapeutic method for pancreatic cancer employing a blood marker. The present invention provides a diagnostic or therapeutic drug for pancreatic cancer containing an anti-AMIGO2 antibody.

Abstract: To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.

Abstract: It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen.

Abstract: The present invention relates to a composition containing as its main component proanthocyanidin oligomer to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded, and reduced in the molecular weight, which is obtained by heating plant materials containing proanthocyanidin polymer or extract thereof with a substance having a phloroglucinol ring structure or resorcinol ring structure in an acidic aqueous solution, production method thereof, and uses of the composition in health products and pharmaceutical products. According to the invention, proanthocyanidin oligomer having physiological activity, to which a substance having a phloroglucinol ring structure or resorcinol ring structure has been bonded and reduced in the molecular weight to such a level that the oligomer can be absorbed into living body, which has been conventionally difficult to obtain at high yield from plant raw materials, can be produced efficiently and easily.

Abstract: An absorptive wound covering protecting material and a method for preparing an absorptive wound covering protecting material are characterized by solidifying a sponge raw solution containing no reinforcement that is obtained by mixing viscose and crystalline mirabilite as main raw materials, or a sponge raw solution obtained by mixing viscose containing a reinforcement comprising natural fibers having a length of at least 5 mm to 40 mm, and crystalline mirabilite as main raw materials, by performing a heat treatment on the sponge raw solution, and then forming the solidified cellulose sponge in a thickness somewhat greater than a desired thickness, and then forming the cellulose sponge in a sheet form having a desired thickness by compressing the cellulose sponge, and, if required, carboxymethylating hydroxyl groups in a glucose unit constituting a cellulose sponge so that a degree of substitution of the hydroxyl groups is from 0.5 to less than 1.0, and then, forming an incision the cellulose sponge.

Abstract: The object is to provide an absorptive wound covering protecting material and a method for preparing the same which is quite excellent in an absorptiveness and a liquid-holding property, and is superior in shape-maintaining ability and strength, and wherein a reinforcement can be used and workability is improved, as well as a hemostatic wound healing effect can be enhanced, compared to an absorptive wound covering protecting material comprising a thinly solidified cellulose sponge.

Abstract: A monoclonal antibody which specifically reacts with D-monomer produced by digesting human fibrinogen with granulocyte elastase and D-domain containing digestion products produced by digesting human stabilized fibrin with granulocyte elastase, but does not react with fibrinogen, or fragment X, Y or E produced by digesting fibrinogen with granulocyte elastase is disclosed. The D-dimer or DD/E complex produced by digestion with granulocyte elastase in a sample from a living body can be analyzed without being interferred with fibrinogen, digestion products of fibrinogen with plasmin, or digestion products of stabilized fibrin with plasmin, using the monoclonal antibody.

Abstract: A first monoclonal antibody which specifically reacts with a human .alpha..sub.2 -plasmin inhibitor complex (PIC) and a human plasminogen; a second monoclonal antibody which reacts with PIC and also with a human .alpha..sub.2 -plasmin inhibitor; a third monoclonal antibody which reacts with PIC, but does not react with a human plasminogen and a human .alpha..sub.2 -plasmin inhibitor; hybridomas which secrete the first to third monoclonal antibodies, and an immunoassay using the first to third monoclonal antibodies.

Abstract: A monoclonal antibody that reacts with a human soluble fibrin but not with a human fibrinogen; a hybridoma that secretes the above antibody; and a method of assaying a human soluble fibrin with the above antibody. It is possible to determine the amount of soluble fibrin in the plasma of a patient specifically, readily and rapidly by agglutination and EIA without being affected by plasma fibrinogen, plasmin-degradation product of fibrinogen, fibrin fragment, and plasmin-degradation product of stabilized fibrin even without pretreating the plasma sample.